Huali Wu

3.3k total citations · 1 hit paper
100 papers, 2.4k citations indexed

About

Huali Wu is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Molecular Biology. According to data from OpenAlex, Huali Wu has authored 100 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pharmacology, 18 papers in Pediatrics, Perinatology and Child Health and 17 papers in Molecular Biology. Recurrent topics in Huali Wu's work include Antibiotics Pharmacokinetics and Efficacy (17 papers), melanin and skin pigmentation (16 papers) and Pharmaceutical studies and practices (9 papers). Huali Wu is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (17 papers), melanin and skin pigmentation (16 papers) and Pharmaceutical studies and practices (9 papers). Huali Wu collaborates with scholars based in United States, China and Japan. Huali Wu's co-authors include Youan Zhang, Xingliang Wang, William C. Zamboni, Stephen W. Jones, Farrell R. Kersey, Timothy J. Merkel, J. Christopher Luft, Adam R. Shields, Andrew Z. Wang and Kevin P. Herlihy and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and ACS Nano.

In The Last Decade

Huali Wu

97 papers receiving 2.4k citations

Hit Papers

Using mechanobiological mimicry of red blood cells to ext... 2011 2026 2016 2021 2011 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Huali Wu United States 29 441 386 366 322 256 100 2.4k
Michael D. Coleman United Kingdom 32 849 1.9× 152 0.4× 26 0.1× 906 2.8× 436 1.7× 153 4.1k
Zhu Zhang China 28 906 2.1× 209 0.5× 61 0.2× 144 0.4× 25 0.1× 149 2.5k
Zhihao Liu China 35 1.6k 3.7× 76 0.2× 111 0.3× 157 0.5× 168 0.7× 239 4.1k
Yukio Kato Japan 45 2.4k 5.4× 103 0.3× 847 2.3× 656 2.0× 1.0k 4.0× 306 7.9k
Young Sup Lee South Korea 34 1.9k 4.3× 31 0.1× 272 0.7× 188 0.6× 42 0.2× 108 4.5k
Ryoji Nagai Japan 47 1.8k 4.1× 224 0.6× 77 0.2× 162 0.5× 71 0.3× 264 6.9k
Shuping Liu China 30 587 1.3× 38 0.1× 27 0.1× 362 1.1× 99 0.4× 154 2.9k
Hua Zhang China 35 1.4k 3.1× 49 0.1× 136 0.4× 517 1.6× 35 0.1× 201 4.3k
Jong Hun Lee South Korea 34 1.7k 3.8× 92 0.2× 144 0.4× 444 1.4× 28 0.1× 180 4.0k
Xiaoqiang Li China 41 1.4k 3.2× 40 0.1× 108 0.3× 195 0.6× 37 0.1× 224 5.1k

Countries citing papers authored by Huali Wu

Since Specialization
Citations

This map shows the geographic impact of Huali Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huali Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huali Wu more than expected).

Fields of papers citing papers by Huali Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Huali Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huali Wu. The network helps show where Huali Wu may publish in the future.

Co-authorship network of co-authors of Huali Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Huali Wu. A scholar is included among the top collaborators of Huali Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Huali Wu. Huali Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
He, Yun, Xiaohong Chen, Shi‐Nan Wu, et al.. (2025). Identifying high-risk drugs and demographic patterns in drug-induced liver injury from FAERS and CVARD analyses. Scientific Reports. 15(1). 40579–40579.
2.
Langel, Stephanie N., Jerry Chang, Lauren E. Williamson, et al.. (2025). Breast milk delivery of an engineered dimeric IgA protects neonates against rotavirus. Mucosal Immunology. 18(2). 441–452. 4 indexed citations
3.
Li, Xiaoye, Lijia Chen, Hong Wang, et al.. (2024). Germacrone, isolated from Curcuma wenyujin, inhibits melanin synthesis through the regulation of the MAPK signaling pathway. Journal of Natural Medicines. 78(4). 863–875. 2 indexed citations
5.
Chen, Hong, Yifan Zhang, Lili Yang, et al.. (2023). Epimedin B exhibits pigmentation by increasing tyrosinase family proteins expression, activity, and stability. Journal of Pharmaceutical Analysis. 14(1). 69–85. 3 indexed citations
6.
Wang, Maolin, Yifu Yang, Liang Chen, et al.. (2023). Ursolic acid derivative UAOS-Na treats experimental autoimmune encephalomyelitis by immunoregulation and protecting myelin. Frontiers in Neurology. 14. 1269862–1269862. 4 indexed citations
7.
Maharaj, Anil R., Huali Wu, Kanecia O. Zimmerman, et al.. (2021). Pharmacokinetics of Ceftazidime in Children and Adolescents with Obesity. Pediatric Drugs. 23(5). 499–513. 4 indexed citations
8.
Yang, Lili, et al.. (2020). Electrocautery Needling and the 308-nm Excimer Lamp: A Synergistic Combination for the Treatment of Stable Non-segmental Vitiligo. Dermatology and Therapy. 10(4). 695–705. 7 indexed citations
9.
Maharaj, Anil R., Huali Wu, Christoph P. Hornik, et al.. (2020). Use of normalized prediction distribution errors for assessing population physiologically-based pharmacokinetic model adequacy. Journal of Pharmacokinetics and Pharmacodynamics. 47(3). 199–218. 9 indexed citations
10.
Maharaj, Anil R., Huali Wu, Kanecia O. Zimmerman, et al.. (2020). Population pharmacokinetics of olanzapine in children. British Journal of Clinical Pharmacology. 87(2). 542–554. 9 indexed citations
11.
12.
Zhou, Liangliang, et al.. (2018). The different roles of 5-HT1A/2A receptors in fluoxetine ameliorated pigmentation of C57BL/6 mouse skin in response to stress. Journal of Dermatological Science. 92(3). 222–229. 16 indexed citations
13.
Wang, Qian, Huali Wu, Jia Zhou, et al.. (2018). Involvement of the central hypothalamic-pituitary-adrenal axis in hair growth and melanogenesis among different mouse strains. PLoS ONE. 13(10). e0202955–e0202955. 6 indexed citations
14.
Wu, Huali, Qiongzhen Liu, Praveen Kumar Kalavagunta, et al.. (2017). Normal diet Vs High fat diet - A comparative study: Behavioral and neuroimmunological changes in adolescent male mice.. Metabolic Brain Disease. 33(1). 177–190. 59 indexed citations
15.
Wu, Huali, et al.. (2016). Specific Data Mining Algorithm Based on Fuzzy Constraint Database. 33(10). 375. 2 indexed citations
16.
Wu, Huali, Jeffrey R. Infante, Vicki L. Keedy, et al.. (2015). Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors. International Journal of Nanomedicine. 10. 1201–1201. 14 indexed citations
17.
Wu, Huali, et al.. (2014). Tetracycline Residues in Porcine Stomach after Administration via Drinking Water on a Swine Farm. Journal of Food Protection. 77(1). 122–126. 6 indexed citations
18.
Leavens, Teresa L., Lisa A. Tell, Lindsey W. Kissell, et al.. (2014). Development of a physiologically based pharmacokinetic model for flunixin in cattle (Bos taurus). Food Additives & Contaminants Part A. 31(9). 1506–1521. 36 indexed citations
19.
Wu, Huali, Ramesh K. Ramanathan, Beth A. Zamboni, et al.. (2011). Population Pharmacokinetics of Pegylated Liposomal CKD‐602 (S‐CKD602) in Patients With Advanced Malignancies. The Journal of Clinical Pharmacology. 52(2). 180–194. 30 indexed citations
20.
Strychor, Sandra, et al.. (2009). Pharmacokinetic Study of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies. Clinical Pharmacology & Therapeutics. 86(5). 519–526. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026